Human inhibitory anti-factor VIII antibodies binding to the A2 domain

Details for Australian Patent Application No. 2006278838 (hide)

Owner Life Sciences Research Partners VZW

Inventors Gilles, Jean Guy; Jacquemin, Marc; Saint-Remy, Jean-Marie

Agent Spruson & Ferguson

Pub. Number AU-B-2006278838

PCT Pub. Number WO2007/017154

Priority 0516055.1 04.08.05 GB; 0515637.7 29.07.05 GB

Filing date 31 July 2006

Wipo publication date 15 February 2007

Acceptance publication date 23 December 2010

International Classifications

C07K 16/36 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 7/02 (2006.01) Drugs for disorders of the blood or the extracellular fluid

Event Publications

28 February 2008 PCT application entered the National Phase

  PCT publication WO2007/017154 Priority application(s): WO2007/017154

23 December 2010 Application Accepted

  Published as AU-B-2006278838

27 January 2011 Application for Amendment

  The nature of the amendment is as shown in the statement(s) filed 22 Dec 2010. Address for service in Australia - Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000

26 May 2011 Standard Patent Sealed

23 February 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006278843-Method for producing urea pellets

2006278829-GSK-3 inhibitors